Doxazosin
Cardura, Doxazosin
alpha-Adrenergic Blocker
NADAC/unit
$0.0693
No Shortage
Tier 1: 200.6%
9 Manufacturers
36 ANDAs
an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH....
vs. brand Cardura: Generic saves up to 99% per unit
Market Intelligence
2026-02-18 Class III Recall: Unichem Pharmaceuticals USA Inc.
2025-01-22 Class II Recall: Viatris Inc
2025-01-22 Class II Recall: Viatris Inc
2023-05-03 Class II Recall: Northwind Pharmaceuticals LLC
2023-03-08 Class II Recall: Accord Healthcare, Inc.
Generic Manufacturers
ACCORD HEALTHCARE INCAPOTEX INCAUROBINDO PHARMA USA INCHERITAGE PHARMA LABS INCRISING PHARMA HOLDINGS INCSOMERSET THERAPEUTICS LLCTEVA PHARMACEUTICALS USA INCUNICHEM LABORATORIES LTDVIATRIS SPECIALTY LLCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.